NewGen Issues Clarification on Press Release Titled “NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director” dated February 20, 2025
20 Fevereiro 2025 - 6:30PM
NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”)
today issued a clarification that, in the press release titled
“NewGen Receives Continued Nasdaq Listing Approval and Announces
New Business Development Director” issued on February 20, 2025, the
Company did not intend to imply that it has already achieved
compliance with the Nasdaq Capital Market’s $2.5 million minimum
stockholders’ equity requirement (the “Equity Rule”). However,
during its 1st quarter to date, certain NewGen debtholders
converted $2.3 million of debt to equity and the Company has drawn
down approximately $4.3 million from its Equity Line of Credit with
White Lion Capital. Therefore, the Company believes it has in
excess of $2.5 million in stockholders’ equity as of this date. The
Company is awaiting confirmation from Nasdaq that it has evidenced
compliance with the Equity Rule. However, there can be no
assurance that Nasdaq will determine that the Company has regained
compliance with the Nasdaq continued listing rules.
NewGen further confirms that the Nasdaq Hearings Panel (the
"Panel") granted an extension, allowing the Company additional time
to regain compliance with Nasdaq’s continued listing requirements,
subject to meeting specific compliance criteria within designated
timeframes. In accordance with the Panel’s extension, the Company
has already made progress on its compliance plan (along with the
update on the Equity Rule already noted above), including carrying
out a reverse split on February 11, 2025 in order to regain
compliance with the $1.00 bid price requirement (NewGen’s closing
bid price has traded above $1.00 for six consecutive trading days
as of February 19, 2025). The Company also intends to apply for
transition to the Nasdaq Capital Market on or before February
26, 2025.
About NewGen
NewGen is a comprehensive fertility services provider in Asia
helping couples and individuals obtain access to fertility
treatments. With a mission to aid couples and individuals in
building families regardless of fertility challenges, NewGen has
dedicated itself to creating increased access to infertility
treatment and providing comprehensive fertility services for its
customers. NewGen’s management team collectively has over a decade
of experience in the fertility industry. NewGen’s clinics are
located in Thailand, Cambodia, and Kyrgyzstan, and present a full
suite of services for its patients, including comprehensive
infertility and assisted reproductive technology treatments, egg
and sperm donation, and surrogacy, in the appropriate
jurisdictions, respectively. To learn more, visit
www.newgenivf.com. The information contained on, or accessible
through, NewGen’s website is not incorporated by reference into
this press release, and you should not consider it a part of this
press release.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Without limiting the generality of the
foregoing, the forward-looking statements in this press release
include descriptions of the Company’s future commercial operations,
business strategy, and financial condition. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release. You should carefully consider the foregoing factors and
the other risks and uncertainties described in the Company’s annual
report on Form 20-F and other documents filed or to be filed by the
Company with the SEC from time to time, which could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Copies of these documents are available
on the SEC’s website, www.sec.gov. All information provided herein
is as of the date of this press release, and the Company undertakes
no obligation to update any forward-looking statement, except as
required under applicable law.
Investor Relations Contact
ICR, LLCRobin YangPhone: +1 (212)
537-4406Email: Newgenivf.IR@icrinc.com
NewGenIvf (NASDAQ:NIVF)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
NewGenIvf (NASDAQ:NIVF)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025